ATLANTA—The RTS,S/AS01 candidate malaria vaccine — being tested in seven African countries — is safe, and gave protection to a third of all babies vaccinated between the ages of six and 12 weeks during the first year of follow up. These findings were announced at the American Society of Tropical Medicine and Hygiene annual meeting in Atlanta, Georgia, by Dr Patricia Njuguna from the Kenya Medical Research Institute in Kilifi, Kenya and Dr John Lusingu of the National Institute for Medical Research in Tanga, Tanzania. The researchers explain that — together with previous findings in children vaccinated between five and 17 months of age —these interim results demonstrate that RTS,S/AS01 could become an important component of malaria control combined with other measures including effective treatment and the use of insecticide-treated bed nets.
You may also like...
Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes 27 Apr, 2015 No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed 20 Apr, 2015 London School of Hygiene & Tropical Medicine Audio News 16 Aug, 2007 Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015
- Previous story Malaria vaccine prevents one third of malaria cases at 12 months
- Next story MDFM News: ALZHEIMER’S DISEASE: Newly discovered mutation drastically increases risk and points to future treatments
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014